NM_004360.5(CDH1):c.389C>G (p.Ala130Gly) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Sep 17, 2021
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002357446.2

Allele description [Variation Report for NM_004360.5(CDH1):c.389C>G (p.Ala130Gly)]

NM_004360.5(CDH1):c.389C>G (p.Ala130Gly)

Gene:

CDH1:cadherin 1 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

16q22.1

Genomic location:

Preferred name:

NM_004360.5(CDH1):c.389C>G (p.Ala130Gly)

HGVS:

NC_000016.10:g.68808425C>G
NG_008021.1:g.76134C>G
NM_001317184.2:c.389C>G
NM_001317185.2:c.-1227C>G
NM_001317186.2:c.-1431C>G
NM_004360.5:c.389C>GMANE SELECT
NP_001304113.1:p.Ala130Gly
NP_004351.1:p.Ala130Gly
NP_004351.1:p.Ala130Gly
LRG_301t1:c.389C>G
LRG_301:g.76134C>G
LRG_301p1:p.Ala130Gly
NC_000016.9:g.68842328C>G
NM_004360.3:c.389C>G

Protein change:

A130G

Molecular consequence:

NM_001317185.2:c.-1227C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001317186.2:c.-1431C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001317184.2:c.389C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_004360.5:c.389C>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002620929	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Sep 17, 2021)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002620929

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Sep 17, 2021)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV002620929.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.A130G variant (also known as c.389C>G), located in coding exon 4 of the CDH1 gene, results from a C to G substitution at nucleotide position 389. The alanine at codon 130 is replaced by glycine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine